Biodesix, Inc. BDSX 深 沪
已收盘 07-02 16:00:00 美东时间
21.99
-2.510
-10.24%
华盛通- 最 高24.73
- 今 开24.52
- 成交量 6.27万股
- 最 低 21.70
- 昨 收 24.50
- 总市值 2.28亿
- 52周最高 24.9154
- 市盈率 静 --
- 换手率 0.61%
- 52周最低 5.26
- 委 比 -99.80%
- 总股本 1035.58万
- 历史最高 639.80
- 量 比 0.39
- 振 幅 12.37%
- 历史最低 3.436
- 每 手 1
- 风险率 4.05%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅135.66%！Ocular Therapeutix获Chardan Capital升目标价至23美元，维持"买入"评级
今日重点评级关注：Chardan Capital：维持Ocular Therapeutix"买入"评级，目标价从21美元升至23美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从30美元升至40美元
06-26 17:42
Roth Capital Initiates Coverage On Biodesix with Buy Rating, Announces Price Target of $32
Roth Capital analyst Max Masucci initiates coverage on Biodesix (NASDAQ:BDSX) with a Buy rating and announces Price Target of $32.
06-25 19:00
美股大行评级 | 大摩再上调希捷科技和西部数据目标价；多家大行首予Lincoln买入评级
今日重点评级关注：HC Wainwright & Co.：维持Elicio Therapeutics"买入"评级，目标价从17美元升至23美元；Leerink Partners：维持SAB Biotherapeutics"跑赢大市"评级，目标价从7美元升至12美元
06-16 11:34
HC Wainwright & Co. Initiates Coverage On Biodesix with Buy Rating, Announces Price Target of $26
HC Wainwright & Co. analyst Yi Chen initiates coverage on Biodesix (NASDAQ:BDSX) with a Buy rating and announces Price Target of $26.
06-15 18:17
Biodesix to Participate in Upcoming Investor Conferences
Biodesix, Inc. announced that its leadership team will participate in three upcoming investor conferences: the Craig-Hallum 23rd Annual Institutional Investor Conference on May 28, 2026, in Minneapolis; the William Blair 46th Annual Growth Stock Conference on June 3, 2026, in Chicago; and the TD Cowen Annual Tools/Dx Revolution on June 24, 2026, in Dana Point. The events will feature presentations and 1x1 meetings, with a live webcast available o...
05-21 10:00
美股大行评级 | Stifel上调Lumentum控股目标价从800美元升至1100美元；Pinterest、先进能源工业、安森美半导体、莱迪思半导体、V2X等获多家大行上调目标价
今日重点评级关注：Piper Sandler：维持Aclaris Therapeutics"超配"评级，目标价从7美元升至11美元；Evercore ISI集团：维持BioMarin Pharmaceutical"跑赢大市"评级，目标价从110美元升至120美元
05-06 11:29
Biodesix Q1 2026 Earnings Call: Complete Transcript
Biodesix (NASDAQ:BDSX) released first-quarter financial results and hosted an e...
05-05 05:23
Biodesix shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY26 sales guidance with its midpoint above estimates.
Biodesix shares are trading higher after the company reported better-than-expec...
05-05 04:58
Biodesix Raises FY2026 Sales Guidance from $106.000M-$112.000M to $108.000M-$114.000M vs $108.680M Est
Biodesix (NASDAQ:BDSX) raises FY2026 sales outlook from $106.000 million-$112.000 million to $108.000 million-$114.000 million vs $108.680 million estimate.
05-05 04:02
Biodesix Announces First Quarter 2026 Results and Highlights
Biodesix reported Q1 2026 revenue of $25.6 million, a 42% year-over-year increase, with a 84% gross margin. The company raised its FY 2026 revenue guidance to $108-114 million, reflecting a 25% growth midpoint. Both diagnostic testing and development services saw strong growth, with test volumes up 29% and development revenue doubling. Biodesix also highlighted its recognition as a Top Workplace for the third consecutive year and plans to host a ...
05-04 20:01
